Uptake of the HPV vaccine among people with and without HIV, cisgender and transgender women and men who have sex with men and with women at two sexual health clinics in Mexico City

References

• Pahud BA, Ault KA. The expanded impact of human papillomavirus vaccine. Infect Dis Clin North Am. 2015 Dec;29(4):715–24. doi:10.1016/j.idc.2015.07.007.
   PubMed Web of Science ®Google Scholar
• Dunne EF, Markowitz LE, Saraiya M, Stokley S, Middleman A, Unger ER, Williams A, Iskander J. Centers for disease control and prevention (CDC). CDC grand rounds: reducing the burden of HPV-associated cancer and disease. MMWR Morb Mortal Wkly Rep. 2014 Jan 31;63(4):69–72.
   PubMed Web of Science ®Google Scholar
• Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017 May 5;66(11):1–28. doi:10.15585/mmwr.ss6611a1.
   PubMed Web of Science ®Google Scholar
• Steben M, Garland SM. Genital warts. Best Pract Res Clin Obstet Gynaecol. 2014 Oct;28(7):1063–73. doi:10.1016/j.bpobgyn.2014.07.002.
   PubMed Web of Science ®Google Scholar
• Flores-Díaz E, Sereday KA, Ferreira S, Sirak B, Sobrinho JS, Baggio ML, Galan L, Silva RC, Lazcano-Ponce E, Giuliano AR et al. The HIM study group. HPV-11 variability, persistence and progression to genital warts in men: the HIM study. J Gen Virol. 2017 Sep;98(9):2339–42. doi:10.1099/jgv.0.000896.
   PubMed Web of Science ®Google Scholar
• Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012 Nov 20;30(Suppl 5):F12–23.
   PubMed Web of Science ®Google Scholar
• Raghavendran A, Hernandez AL, Lensing S, Gnanamony M, Karthik R, Sivasubramanian M, Kannangai R, Abraham P, Mathai D, Palefsky JM. Genital human papillomavirus infection in Indian HIV-seropositive men who have sex with men. Sex Transm Dis. 2017 Mar;44(3):173–80. doi:10.1097/OLQ.0000000000000564.
   PubMed Web of Science ®Google Scholar
• Nyitray AG, Da Silva RJ, Baggio ML, Lu B, Smith D, Abrahamsen M, Papenfuss M, Quiterio M, Villa LL, Giuliano AR. The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sex Transm Dis. 2011 Oct;38(10):932–40. doi:10.1097/OLQ.0b013e31822154f9.
   PubMed Web of Science ®Google Scholar
• Loverro G, Di Naro E, Caringella AM, De Robertis AL, Loconsole D, Chironna M. Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy. Sex Transm Infect. 2016 Feb;92(1):67–69. doi:10.1136/sextrans-2014-051987.
   PubMed Web of Science ®Google Scholar
• Thompson AB, Gillespie SE, Mosunjac MB, Hussen SA, Flowers LC, Camacho-Gonzalez AF. Prevalence of anal squamous intraepithelial lesions in HIV-1-infected young men who have sex with men and transwomen. J Low Genit Tract Dis. 2018 Oct;22(4):340–47. doi:10.1097/LGT.0000000000000437.
   PubMed Web of Science ®Google Scholar
• Combes JD, Clifford GM, Egger M, Cavassini M, Hirsch HH, Hauser C, Calmy A, Schmid P, Bernasconi E, Günthard HF et al. Swiss HIV cohort study. Human papillomavirus antibody response following HAART initiation among MSM. AIDS. 2017 Feb 20;31(4):561–69. doi:10.1097/QAD.0000000000001354.
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Sudenga SL, Torres BN, Stoler M, León-Maldonado L, Allen-Leigh B, Posso H, Quiterio M, Hernández-Nevarez MP, Salmerón J, et al. Incidence of external genital lesions related to human papillomavirus among Mexican men. A Cohort Study Salud Publica Mex. 2018 Nov-Dec;60(6):633–44. doi:10.21149/8461.
   PubMed Web of Science ®Google Scholar
• Posso H, León-Maldonado L, Allen-Leigh B, Salmerón J, Quiterio M, Giuliano AR, Sudenga SL, Nyitray AG, Torres BN, Abrahamsen M, et al. Prevalence and incidence of anal human papillomavirus infection in Mexican men: need for universal prevention policies. Salud Publica Mex. 2018 Nov-Dec;60(6):645–52. doi:10.21149/8454.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, Hillman RJ, Petoumenos K, Roberts J, Tabrizi SN et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012 May;13(5):487–500. doi:10.1016/S1470-2045(12)70080-3.
   PubMed Web of Science ®Google Scholar
• Rosario M, Corliss HL, Everett BG, Reisner SL, Austin SB, Buchting FO, Birkett M. Sexual orientation disparities in cancer-related risk behaviors of tobacco, alcohol, sexual behaviors, and diet and physical activity: pooled youth risk behavior surveys. Am J Public Health. 2014 Feb;104(2):245–54. doi:10.2105/AJPH.2013.301506.
   PubMed Web of Science ®Google Scholar
• Brown B, Monsour E, Klausner JD, Galea JT. Sociodemographic and behavioral correlates of anogenital warts and human papillomavirus-related knowledge among men who have sex with men and transwomen in Lima, Peru. Sex Transm Dis. 2015 Apr;42(4):198–201. doi:10.1097/OLQ.0000000000000258.
   PubMed Web of Science ®Google Scholar
• McCloskey JC, Kast WM, Flexman JP, McCallum D, French MA, Phillips M. Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. Papillomavirus Res. 2017 Dec;4:90–98. doi:10.1016/j.pvr.2017.10.004.
   PubMed Web of Science ®Google Scholar
• Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003 Dec;17(4):423–41.
   PubMed Web of Science ®Google Scholar
• van Aar F, Mooij SH, van der Sande MA, Speksnijder AG, Stolte IG, Meijer CJ, Verhagen DW, King AJ, de Vries HJ, Schim van der Loeff MF. Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. AIDS. 2013 Nov 28;27(18):2921–31. doi:10.1097/01.aids.0000432541.67409.3c.
   PubMed Web of Science ®Google Scholar
• Quinn GP, Sanchez JA, Sutton SK, Vadaparampil ST, Nguyen GT, Green BL, Kanetsky PA, Schabath MB. Cancer and lesbian, gay, bisexual, transgender/ transsexual,and queer/questioning (LGBTQ) populations. CA Cancer J Clin. 2015 Sep-Oct;65(5):384–400. doi:10.3322/caac.21288.
   PubMed Web of Science ®Google Scholar
• Leonard D, Beddy D, Dozois EJ. Neoplasms of anal canal and perianal skin. Clin Colon Rectal Surg. 2011 Mar;24(1):54–63. doi:10.1055/s-0031-1272824.
   PubMedGoogle Scholar
• Hernandez AL, Efird JT, Holly EA, Berry JM, Jay N, Palefsky JM. Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):532–39. doi:10.1097/QAI.0b013e3182968f87.
   PubMed Web of Science ®Google Scholar
• Minkoff H, Zhong Y, Strickler HD, Watts DH, Palefsky JM, Levine AM, D’Souza G, Howard AA, Plankey M, Massad LS, et al. The relationship between cocaine use and human papillomavirus infections in HIV-seropositive and HIV-seronegative women. Infect Dis Obstet Gynecol. 2008;2008:587082. doi:10.1155/2008/587082.
   PubMedGoogle Scholar
• Adedimeji A, Sinayobye JD, Asiimwe-Kateera B, Chaudhry J, Buzinge L, Gitembagara A, Murenzi G, Mugenzi P, Patel VV, Castle PE, et al. Social contexts as mediator of risk behaviors in Rwandan men who have sex with men (MSM): implications for HIV and STI transmission. PLoS One. 2019 Jan 18;14(1):e0211099. doi:10.1371/journal.pone.0211099.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant]. Merck & Co, Inc: Food and Drug Administration 2009. [accessed May 20 2019]. http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm094042.htm
   Google Scholar
• Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S19–23.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006 Dec 4;95(11):1459–66.
   PubMed Web of Science ®Google Scholar
• Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer. 2007 May 7;96(9):1320–23.
   PubMed Web of Science ®Google Scholar
• Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M,  Perez G, Brown DR, Koutsky LA, Tay EH, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008 Dec 9;26(52):6844–51.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009Oct, 5(10), 696–704.
   PubMed Web of Science ®Google Scholar
• Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–68.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA Jr., Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–04.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine. 2016 Feb 3;34(6):757–61. doi:10.1016/j.vaccine.2015.12.063.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA Jr, Unger ER. Centers for disease control and prevention (CDC). Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014 Aug 29;63(RR–05):1–30.
   PubMed Web of Science ®Google Scholar
• FDA NEWS RELEASE. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. [accessed May 13, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old
   Google Scholar
• Wigle J, Fontenot HB, Zimet GD. Global delivery of human papillomavirus vaccines. Pediatr Clin North Am. 2016 Feb;63(1):81–95. doi:10.1016/j.pcl.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, Fredua B, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909–17. doi:10.15585/mmwr.mm6733a1.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul;4(7):e453–63. doi:10.1016/S2214-109X(16)30099-7.
   PubMed Web of Science ®Google Scholar
• WHO. Upswing in HPV vaccination in Ireland. [accessed 1 September, 2019]. http://www.euro.who.int/en/countries/denmark/news/news/2018/9/upswing-in-hpv-vaccination-in-ireland
   Google Scholar
• WHO. Denmark campaign rebuilds confidence in HPV vaccination. [accessed 1 September, 2019]. https://www.who.int/features/2018/hpv-vaccination-denmark/en/
   Google Scholar
• Danish Health Authority. Sharp fall in HPV vaccination rate. [accessed 1 September, 2019]. https://www.sst.dk/en/news/2016/sharp-fall-in-hpv-vaccination-rate
   Google Scholar
• Programa de Acción Específico 2007–2012. Cáncer cervicouterino. Specific Action Plan 2007–212. Cervical-uterine cancer. México: Secretaría de Salud. Subsecretaría de Prevención y Promoción de la Salud; 2008.
   Google Scholar
• Programa de Acción Específico. Prevención y control del cáncer de la mujer 2013–2018. Programa sectorial de salud. [Specific action program. Prevention and control of women’s cancer 2013–2018. Health sector program]. México: Secretaría de Salud; 2014.
   Google Scholar
• Lazcano-Ponce E, Salmerón-Castro J, García-Carrancá A, Aranda-Flores C, Madrid-Marina V, Gómez-Altamirano CM, Martínez-Montañez OG. Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic advisory group of experts of the world health organization. Salud Publica Mex. 2009 Jul-Aug;51(4):336–41.
   PubMedGoogle Scholar
• Portillo-Romero AJ, León-Maldonado L, Allen-Leigh B, Brown B, Magis C, Garcia Fuentes NB, Salmerón J, Hurtado E, Torres-Ibarra L, Rivera Paredez B, et al. HPV vaccine acceptance is high among adults in Mexico, particularly in people living with. HIV Salud Publica Mex. 2018 Nov-Dec;60(6):658–65. doi:10.21149/10182.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, Quiterio M, Lazcano-Ponce E. Immunogenicity and safety of gardasil among mid-adult aged men (27–45 years)–the MAM study. Vaccine. 2015 Oct 13;33(42):5640–46. doi:10.1016/j.vaccine.2015.08.072.
   PubMed Web of Science ®Google Scholar
• Hernández-Ávila M, Torres-Ibarra L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N, Herrero R, Villaseñor-Ruíz IF, Lazcano-Ponce E. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30–38. doi:10.1080/21645515.2015.1058458.
   PubMed Web of Science ®Google Scholar
• Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C, Lazcano-Ponce E. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan study in Mexico. Salud Publica Mex. 2016;58:211–19.
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Rivera L, Arillo-Santillán E, Salmerón J, Hernández-Avila M, Muñoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 2001 May-Jun;32(3):243–47.
   PubMed Web of Science ®Google Scholar
• Moraros J, Bird Y, Barney DD, King SC, Banegas M, Suarez-Toriello E. A pilot study: HPV infection knowledge & HPV vaccine acceptance among women residing in Ciudad Juárez, México. Californian J Health Promot. 2006;4:177–86.
   Google Scholar
• Ramírez-Rios AD, Bonnez W. Attitudes affecting the potential use of human papillomavirus vaccination: a survey of health promotion students in Mexico City. J Community Health. 2014 Apr;39(2):266–73. doi:10.1007/s10900-013-9770-1.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011 Dec;22(12):2675–86.
   PubMed Web of Science ®Google Scholar
• Elfström KM, Herweijer E, Sundström K, Arnheim-Dahlström L. Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review. Curr Opin Oncol. 2014 Jan;26(1):120–29. doi:10.1097/CCO.0000000000000034.
   PubMed Web of Science ®Google Scholar
• Moss JL, Reiter PL, Brewer NT. Correlates of human papillomavirus vaccine coverage: a state-level analysis. Sex Transm Dis. 2015 Feb;42(2):71–75. doi:10.1097/OLQ.0000000000000225.
   PubMed Web of Science ®Google Scholar
• Timbang MR, Sim MW, Bewley AF, Farwell DG, Mantravadi A, Moore MG. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019 May;3:1–9.
   Google Scholar
• Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, Ferenczy A, Kurman RJ, Ronnett BM, Stoler MH, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019 Apr 11;S0090-8258(19)30488-3.
   PubMed Web of Science ®Google Scholar
• Bednarczyk RA, Whitehead JL, Stephenson R. Moving beyond sex: assessing the impact of gender identity on human papillomavirus vaccine recommendations and uptake among a national sample of rural-residing LGBT young adults. Papillomavirus Res. 2017 Jun;3:121–25. doi:10.1016/j.pvr.2017.04.002.
   PubMed Web of Science ®Google Scholar
• Brown B, Poteat T, Marg L, Galea JT. Human papillomavirus-related cancer surveillance, prevention, and screening among transgender men and women: neglected populations at high risk. LGBT Health. 2017 Oct;4(5):315–19. doi:10.1089/lgbt.2016.0142.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR et al. HPV PATRICIA study group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4.
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915–27.
   PubMed Web of Science ®Google Scholar
• Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health. 2010 Apr;46(4 Suppl):S12–9. doi:10.1016/j.jadohealth.2010.01.010.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry KU, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016 Feb;13(2):119–32. doi:10.1038/nrclinonc.2015.146.
   PubMed Web of Science ®Google Scholar
• Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010 Oct 15;202(8):1246–53. doi:10.1086/656320.
   PubMed Web of Science ®Google Scholar
• Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013 Nov 19;31(48):5745–53. doi:10.1016/j.vaccine.2013.09.032.
   PubMed Web of Science ®Google Scholar
• Poynten IM, Tabrizi SN, Jin F, Templeton DJ, Machalek DA, Cornall A, Phillips S, Fairley CK, Garland SM, Law C, et al., SPANC Study Team. Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men. Papillomavirus Res. 2017 Jun;3:80–84. doi:10.1016/j.pvr.2017.02.003
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010 Apr;46(4 Suppl):S20–6. doi:10.1016/j.jadohealth.2010.01.016.
   PubMed Web of Science ®Google Scholar
• McKirnan DJ, Du Bois SN, Alvy LM, Jones K. Health care access and health behaviors among men who have sex with men: the cost of health disparities. Health Educ Behav. 2013 Feb;40(1):32–41. doi:10.1177/1090198111436340.
   PubMed Web of Science ®Google Scholar
• Roberts TK, Fantz CR. Barriers to quality health care for the transgender population. Clin Biochem. 2014 Jul;47(10–11):983–87. doi:10.1016/j.clinbiochem.2014.02.009.
   PubMed Web of Science ®Google Scholar
• Safer JD, Coleman E, Feldman J, Garofalo R, Hembree W, Radix A, Sevelius J. Barriers to healthcare for transgender individuals. Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):168–71. doi:10.1097/MED.0000000000000227.
   PubMed Web of Science ®Google Scholar
• Nadarzynski T, Smith H, Richardson D, Bremner S, Llewellyn C. Men who have sex with men who do not access sexual health clinics nor disclose sexual orientation are unlikely to receive the HPV vaccine in the UK. Vaccine. 2018 Aug 9;36(33):5065–70. doi:10.1016/j.vaccine.2018.06.075.
   PubMed Web of Science ®Google Scholar
• Nadarzynski T, Smith H, Richardson D, Pollard A, Llewellyn C. Perceptions of HPV and attitudes towards HPV vaccination amongst men who have sex with men: A qualitative analysis. Br J Health Psychol. 2017 May;22(2):345–61. doi:10.1111/bjhp.12233.
   PubMed Web of Science ®Google Scholar
• Cummings T, Kasting ML, Rosenberger JG, Rosenthal SL, Zimet GD, Stupiansky NW. Catching up or missing out? human papillomavirus vaccine acceptability among 18- to 26-year-old men who have sex with men in a US national sample. Sex Transm Dis. 2015 Nov;42(11):601–06. doi:10.1097/OLQ.0000000000000358.
   PubMed Web of Science ®Google Scholar
• Mayer KH, Bradford JB, Makadon HJ, Stall R, Goldhammer H, Landers S. Sexual and gender minority health: what we know and what needs to be done. Am J Public Health. 2008 Jun;98(6):989–95. doi:10.2105/AJPH.2007.127811.
   PubMed Web of Science ®Google Scholar
• Gallup. Wellcome global monitor 2018. First Wave Findings. How does the world feel about science and health? [accessed 1 September, 2019]. https://wellcome.ac.uk/reports/wellcome-global-monitor/2018
   Google Scholar
• Liau A, Stupiansky NW, Rosenthal SL, Zimet GD. Health beliefs and vaccine costs regarding human papillomavirus (HPV) vaccination among a U.S. national sample of adult women. Prev Med. 2012 Mar-Apr;54(3–4):277–79. doi:10.1016/j.ypmed.2012.02.002.
   PubMed Web of Science ®Google Scholar
• Stupiansky NW, Rosenthal SL, Wiehe SE, Zimet GD. Human papillomavirus vaccine acceptability among a national sample of adult women in the USA. Sex Health. 2010 Sep;7(3):304–09. doi:10.1071/SH09127.
   PubMed Web of Science ®Google Scholar
• Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):47–50.
   PubMedGoogle Scholar
• Newman PA, Logie CH, Doukas N, Asakura K. HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect. 2013 Nov;89(7):568–74. doi:10.1136/sextrans-2012-050980.
   PubMed Web of Science ®Google Scholar
• Sadlier C, Lynam A, O’Dea S, Delamere S, Quinlan M, Clarke S, Sheils O, Bergin C. HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland. Hum Vaccin Immunother. 2016 Jun 2;12(6):1536–41. doi:10.1080/21645515.2016.1151588.
   PubMed Web of Science ®Google Scholar
• Cunningham MS, Skrastins E, Fitzpatrick R, Jindal P, Oneko O, Yeates K, Booth CM, Carpenter J, Aronson KJ. Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. BMJ Open. 2015 Mar 10;5(3):e005828. doi:10.1136/bmjopen-2014-005828.
   PubMed Web of Science ®Google Scholar
• Tonguc E, Gungor T, Var T, Kavak E, Yucel M, Uzunlar O. Knowledge about HPV, relation between HPV and cervix cancer and acceptance of HPV vaccine in women in eastern region of Turkey. J Gynecol Oncol. 2013 Jan;24(1):7–13. doi:10.3802/jgo.2013.24.1.7.
   PubMed Web of Science ®Google Scholar
• Wilson R, Brown DR, Boothe MA, Harris CE. Knowledge and acceptability of the HPV vaccine among ethnically diverse black women. J Immigr Minor Health. 2013 Aug;15(4):747–57. doi:10.1007/s10903-012-9749-5.
   PubMed Web of Science ®Google Scholar
• Charakorn C, Rattanasiri S, Lertkhachonsuk AA, Thanapprapasr D, Chittithaworn S, Wilailak S. Knowledge of Pap smear, HPV and the HPV vaccine and the acceptability of the HPV vaccine by Thai women. Asia Pac J Clin Oncol. 2011 Jun;7(2):160–67. doi:10.1111/j.1743-7563.2011.01392.x.
   PubMed Web of Science ®Google Scholar
• Johnson DC, Bhatta MP, Gurung S, Aryal S, Lhaki P, Shrestha S. Knowledge and awareness of human papillomavirus (HPV), cervical cancer and HPV vaccine among women in two distinct Nepali communities. Asian Pac J Cancer Prev. 2014;15:8287–93.
   PubMedGoogle Scholar
• Young AM, Crosby RA, Jagger KS, Richardson MB, Kloha RA, Safarian V. HPV vaccine acceptability among women in the Philippines. Asian Pac J Cancer Prev. 2010;11:1781–87.
   PubMedGoogle Scholar
• Young A. HPV vaccine acceptance among women in the Asian Pacific: a systematic review of the literature. Asian Pac J Cancer Prev. 2010;11:641–49.
   PubMedGoogle Scholar
• Watson-Jones D, Tomlin K, Remes P, Baisley K, Ponsiano R, Soteli S, de Sanjosé S, Changalucha J, Kapiga S, Hayes RJ. Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: a case control study. PLoS One. 2012;7(10):e45231. doi:10.1371/journal.pone.0045231.
   PubMed Web of Science ®Google Scholar
• Cover JK, Nghi NQ, LaMontagne DS, Huyen DT, Hien NT, Nga le T. Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health. 2012 Aug 9;12:629. doi:10.1186/1471-2458-12-629.
   PubMed Web of Science ®Google Scholar
• Bingham A, Drake JK, LaMontagne DS. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med. 2009 May;163(5):455–61. doi:10.1001/archpediatrics.2009.50.
   PubMedGoogle Scholar
• Friedman AL, Oruko KO, Habel MA, Ford J, Kinsey J, Odhiambo F, Phillips-Howard PA, Wang SA, Collins T, Laserson KF, et al. Preparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya. BMC Public Health. 2014 Aug 16;14:855. doi:10.1186/1471-2458-14-855.
   PubMed Web of Science ®Google Scholar
• Fenton AT, Elliott MN, Schwebel DC, Berkowitz Z, Liddon NC, Tortolero SR, Cuccaro PM, Davies SL, Schuster MA. Unequal interactions: examining the role of patient-centered care in reducing inequitable diffusion of a medical innovation, the human papillomavirus (HPV) vaccine. Soc Sci Med. 2018 Mar;200:238–48. doi:10.1016/j.socscimed.2017.09.030.
   PubMed Web of Science ®Google Scholar
• Gerend MA, Shepherd MA, Lustria ML, Shepherd JE. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey. Sex Transm Infect. 2016 Mar;92(2):104–07. doi:10.1136/sextrans-2015-052088.
   PubMed Web of Science ®Google Scholar
• Lau M, Lin H, Flores G. Factors associated with human papillomavirus vaccine-series initiation and healthcare provider recommendation in US adolescent females: 2007 national survey of children’s health. Vaccine. 2012 Apr 26;30(20):3112–18. doi:10.1016/j.vaccine.2012.02.034.
   PubMed Web of Science ®Google Scholar
• Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public Health. 2013 Jan;103(1):164–69. doi:10.2105/AJPH.2011.300600.
   PubMed Web of Science ®Google Scholar
• Burdette AM, Webb NS, Hill TD, Jokinen-Gordon H. Race-specific trends in HPV vaccinations and provider recommendations: persistent disparities or social progress? Public Health. 2017 Jan;142:167–76. doi:10.1016/j.puhe.2016.07.009.
   PubMed Web of Science ®Google Scholar
• Wheldon CW, Daley EM, Walsh-Buhi ER, Baldwin JA, Nyitray AG, Giuliano AR. An integrative theoretical framework for HPV vaccine promotion among male sexual minorities. Am J Mens Health. 2018 Sep;12(5):1409–20. doi:10.1177/1557988316652937.
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Salmerón J, González A, Allen-Leigh B, León-Maldonado L, Magis C, Aranda-Flores C, Conde-González C, Portillo-Romero AJ, Yunes-Díaz E, et al. Prevention and control of neoplasms associated with HPV in high-risk groups in Mexico City: the Condesa Study. Salud Publica Mex. 2018 Nov-Dic;60(6):703–12. doi:10.21149/10034.
   PubMed Web of Science ®Google Scholar
• Malo TL, Hall ME, Brewer NT, Lathren CR, Gilkey MB. Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation. Implement Sci. 2018;13(1):57. doi:10.1186/s13012-018-0743-8.
   PubMed Web of Science ®Google Scholar
• Wigfall LT, Bynum SA, Brandt HM, Hébert JR. HPV vaccine awareness and knowledge among women living with HIV. J Cancer Educ. 2016;31(1):187–90. doi:10.1007/s13187-015-0943-8.
   PubMed Web of Science ®Google Scholar
• Perez S, Zimet GD, Tatar O, Stupiansky NW, Fisher WA, Rosberger Z. Human papillomavirus vaccines: successes and future challenges. Drugs. 2018;78(14):1385–96. doi:10.1007/s40265-018-0975-6.
   PubMed Web of Science ®Google Scholar
• Fenton AT, Eun TJ, Clark JA, Perkins RB. Indicated or elective? The association of providers’ words with HPV vaccine receipt. Hum Vaccin Immunother. 2018:1–7. doi:10.1080/21645515.2018.1480237.
   PubMed Web of Science ®Google Scholar
• Apaydin KZ, Fontenot HB, Shtasel D, Dale SK, Borba CPC, Lathan CS, Panther L, Mayer KH, Keuroghlian AS. Facilitators of and barriers to HPV vaccination among sexual and gender minority patients at a Boston community health center. Vaccine. 2018 Jun 18;36(26):3868–75. doi:10.1016/j.vaccine.2018.02.043.
   PubMed Web of Science ®Google Scholar
• Thompson EL, Rosen BL, Maness SB. social determinants of health and human papillomavirus vaccination among young adults, national health interview survey 2016. J Community Health. 2019 Feb;44(1):149–58. doi:10.1007/s10900-018-0565-2.
   PubMed Web of Science ®Google Scholar
• Agénor M, Peitzmeier SM, Gordon AR, Charlton BM, Haneuse S, Potter J, Austin SB. Sexual orientation identity disparities in human papillomavirus vaccination initiation and completion among young adult US women and men. Cancer Causes Control. 2016 Oct;27(10):1187–96. doi:10.1007/s10552-016-0796-4.
   PubMed Web of Science ®Google Scholar
• Apaydin KZ, Fontenot HB, Borba CPC, Shtasel DL, Ulery S, Mayer KH, Keuroghlian AS. Three-dose HPV vaccine completion among sexual and gender minority young adults at a Boston community health center. Vaccine. 2018 Aug 6;36(32 Pt B):4897–903. doi:10.1016/j.vaccine.2018.06.057.
   PubMed Web of Science ®Google Scholar
• McRee AL, Gower AL, Reiter PL. Preventive healthcare services use among transgender young adults. Int J Transgend. 2018;19(4):417–23. doi:10.1080/15532739.2018.1470593.
   PubMedGoogle Scholar